Nineteen Twenty-One

Helping make diabetes suck less.

A company led by Fredrik Debong, serial entrepreneur and angel, whose work already impacted millions in the field of diabetes, fintech and innovation management.

Profile image of Fredrik Debong
Logo of hi.health. Abusing fintech in health insurance. Founded in 2019
Logo of mysugr.com. Mobile diabetes management making diabetes suck less. Founded in 2011, exited in 2017.
Logo of pioneers.io. Founded in 2010, exited in 2018.
We finished in the top 2% of VC Lab cohort 16

Companies We Have Invested In

People We Work With And For

One does not do diabetes alone. One does not help companies on ones own. Our approach to taking on diabetes care challenges and delivering a return to limited partners utilizes a global network of industry professionals, from clinicians and patients to researchers and policymakers, from angel savants to GP's of huge VC funds and bankers, from grass root advocates to leaders of global policy organisations. Most of us live with T1D ourself.

Through our collaborative strategy, built upon my founding experience as an operator of several successful startups, Nineteen Twenty-One is providing the next generation of problem solvers with capital and know-how.

Renza Siciblia, Global Access, JDRF, AU/USA
Bastian Hauck, Founder and chief wrangler of #dedoc°
PD Dr. med. Katarina Braune, Charité Berlin, Germany
Dr. Martin Tauschmann, WMU, Austria
Prof. Dr. Othmar Moser, Bayreuth University, Germany
Rayhan A. Lal, MD Assistant Professor of Medicine (Endocrinology) and of Pediatrics (Endocrinology)
Prof. Dr. Marc Breton, UVA, USA
Dr. Howard Zisser, the sage of diabetes technology, USA
Bruce Taylor, former Senior Director Gov Affairs at Dexcom, Director Policy at Roche Diabetes Care US, USA
Antonio Estrella, Health Equity at World Economic Forum
Dr. Sufyan Hussain, Kings College London, UK
Dr. Julia Mader, MUG, Austria
Jeff Hitchcock, Founder and President of Children With Diabetes
Melissa Ford-Holloway, Smart Start Ltd, London, UK
Tim Street, T1D tech critic by night, Quant Trader by day
Kamil Armacky, Finance guy by day, diabetes youtuber by night
Amy Tendrich, Founder and Editor of Diabetes Mine
Dan Taylor, communications and media god who GETS it
Frank Westermann, cofounder and CEO 9am.health, cofounder and x-CEO mySugr
Phil Southerland, diabetes advocate and ceo of Super Sapiens
Leif Bowman, CEO allezhealth.com
Dr. Bernhard Schandl, CTO 9am.health, formerly of mysugr.com, teaching at FH Technikum, Vienna
Clemens Helm, DevAcademy, fullstack developer deluxe
Onno Faber, founder of RareBase. An amazing driven entrepreneur who, like Fred, works on solving his own problems.
Christian Hein, Board Director of SNOMED, formerly VP Digital of Novartis, Director Digital Amgen
Dr. Dietmar Schaffarczyk, Lead Auditor, QSI, Lecturer ETH Zurich
Mag. Martin Schmid, CEO and founder of encotec, AT
Sylvana Sinha, Esq, CEO of Praava Health, Bangladesh
Daniel Hefel, CEO MedNeo
Linus Drop, founder and CEO of Lillian Care, DE
Dr. Jörg Hölzing, CEO CGC Genomics, former SVP Roche Diabetes Care
Andreas Klinger, GP Prototype Capital, founding team & CTO of Product Hunt, VPE of CoinList, Head of Remote at AngelList, and CTO at On Deck
Agate Freimanne, GP of Norrsken Ventures
Tim Jürgens, former VP Roche Diabetes Care, Angel, Partner SeedLink Capital, ES
Tanja Dowe, MD at Angelini Ventures
Christophe Maire, Founder & Managing Partner at Atlantic Labs & FoodLabs
Michael Schuster, founder of Boardroom and…… well he's been a busy guy, check him out :)

And many more <3

Get in Touch

If you’re as passionate about revolutionizing diabetes care as we are, we should talk.

Before we go into specifics we need to know if you are an accredited, qualified, professional, sophisticated investor.

It's the law and Fred's a compliance guy.

Nineteen Twenty
One

Investing in making diabetes suck less

1921.vc

© 2024 Fredrik Debong

Imprint: Fredrik Debong, for now, A-1190 Vienna, Austria. Commercial court: Handelsgericht Vienna

Contact:
Nineteen Twenty GmbH in Gründung | TBD
1921 I EuVECA GmbH & Co. KG | 644756x
Wasagasse 11 / 9
1090 Vienna
Austria

Court of Jurisdiction: Vienna Commercial Court
Email: fred@1921.vc
Phone: +4369911033609
Website: 1921.vc

Privacy Policy
At 1921.vc, we take your privacy seriously. We do not use cookies or tracking technologies on our website. Any personal data you provide (e.g., through contact forms) will be handled in compliance with the General Data Protection Regulation (GDPR).

We collect and process:
- Name and contact details (if you submit them via forms).
- Email addresses for communication purposes.

Your data will not be shared with third parties unless required by law. You have the right to request access, correction, or deletion of your data at any time by contacting us at fred@1921.vc.

Terms of Service
Welcome to 1921.vc. By using our website, you agree to the following terms:
- The content provided on this site is for informational purposes only and does not constitute financial or investment advice.
- You may not copy, reproduce, or distribute any content from this site without permission.
- We reserve the right to modify these terms at any time.

For any questions regarding the use of this website, please contact us at fred@1921.vc

Third Party Tools

We use pagy.co to build and maintain our super simple website. Built by this guy Manny and he seems a nice chap ;) Oh and as no sensitive information is requested by us we are fine with this service built by one guy simply not stating much about how they handle things, and will assume you are too. We're in touch to help him rectify this, but give the guy a break, for now.

For further details, please reach out to our Data Protection Officer, fred@1921.vc.

Cookie Disclaimer

We… don't use cookies. We simply are not good at baking, or see the need of them on this site.
But if you REALLY want a disclaimer, please write one on a postit and slap it on your screen :)

Disclaimer
1921 VC is an EUVECA-registered venture capital fund operating under the European Venture Capital Fund (EUVECA) Regulation (EU) No. 345/2013. The information provided on this website is intended exclusively for professional investors as defined under Directive 2014/65/EU (MiFID II) and other eligible investors who meet the requirements of the EUVECA framework.

Investor Eligibility
Investment opportunities offered by 1921 VC are not open to the general public and are restricted to:
✅ Professional investors, including institutional investors, family offices, and asset managers
✅ High-net-worth individuals (HNWIs) who commit a minimum of €100,000 and acknowledge the associated risks
✅ Other eligible investors as defined by the EuVECA regulation

No Public Offering
The content on this website does not constitute an offer to sell or a solicitation to invest in any jurisdiction where such an offer or solicitation would be unlawful. This website is provided for informational purposes only and should not be construed as investment, legal, or tax advice.

Risk Warning
Investing in venture capital involves a high degree of risk, including the risk of total loss of capital. Past performance is not indicative of future results. Prospective investors should consult their own financial, legal, and tax advisors before making an investment decision.

By visiting this page, you confirm that:
✅ You are a professional investor or an eligible investor under EUVECA rules
✅ You understand the risks associated with venture capital investments
✅ You acknowledge that this website does not constitute an investment offer
OR
✅ You were asked for feedback on the page!